Rocket Pharmaceuticals (NASDAQ:RCKT) has treated the first patient in the higher-dose cohort in its Phase 1 clinical trial of RP-A501, an adeno-associated viral vector (AAV)-based gene therapy for the treatment of Danon disease, a rare inherited disorder characterized by weakening of heart and skeletal muscles.
The second cohort evaluates RP-A501 at a higher-dose level of 1.1×1014 genome copies/kilogram in male patients 15 years of age and older. The Phase 1 study will assess the safety, tolerability and preliminary efficacy of RP-A501.
Treatment of the higher-dose cohort comes after successful completion of the low-dose cohort and FDA clearance.
Following the review of safety data from the first cohort, all subsequent cohorts will include 2-4 patients per cohort, adjusted down from 3-6 patients in the original protocol.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.